Literature DB >> 29976766

Serum Amyloid A Is an Exchangeable Apolipoprotein.

Patricia G Wilson1,2,3, Joel C Thompson1,2,3, Preetha Shridas4,2,3, Patrick J McNamara5, Maria C de Beer6,2,3, Frederick C de Beer4,2,3, Nancy R Webb1,7,2,3, Lisa R Tannock1,4,2,3.   

Abstract

Objective- SAA (serum amyloid A) is a family of acute-phase reactants that have proinflammatory and proatherogenic activities. SAA is more lipophilic than apoA-I (apolipoprotein A-I), and during an acute-phase response, <10% of plasma SAA is found lipid-free. In most reports, SAA is found exclusively associated with high-density lipoprotein; however, we and others have reported SAA on apoB (apolipoprotein B)-containing lipoproteins in both mice and humans. The goal of this study was to determine whether SAA is an exchangeable apolipoprotein. Approach and Results- Delipidated human SAA was incubated with SAA-free human lipoproteins; then, samples were reisolated by fast protein liquid chromatography, and SAA analyzed by ELISA and immunoblot. Both in vitro and in vivo, we show that SAA associates with any lipoprotein and does not remain in a lipid-free form. Although SAA is preferentially found on high-density lipoprotein, it can exchange between lipoproteins. In the presence of CETP (cholesterol ester transfer protein), there is greater exchange of SAA between lipoproteins. Subjects with diabetes mellitus, but not those with metabolic syndrome, showed altered SAA lipoprotein distribution postprandially. Proteoglycan-mediated lipoprotein retention is thought to be an underlying mechanism for atherosclerosis development. SAA has a proteoglycan-binding domain. Lipoproteins containing SAA had increased proteoglycan binding compared with SAA-free lipoproteins. Conclusions- Thus, SAA is an exchangeable apolipoprotein and increases apoB-containing lipoproteins' proteoglycan binding. We and others have previously reported the presence of SAA on low-density lipoprotein in individuals with obesity, diabetes mellitus, and metabolic syndrome. We propose that the presence of SAA on apoB-containing lipoproteins may contribute to cardiovascular disease development in these populations.

Entities:  

Keywords:  apolipoproteins; atherosclerosis; inflammation; metabolic syndrome; models, animal

Mesh:

Substances:

Year:  2018        PMID: 29976766      PMCID: PMC6202200          DOI: 10.1161/ATVBAHA.118.310979

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  57 in total

1.  SAA does not induce cytokine production in physiological conditions.

Authors:  Myung-Hee Kim; Maria C de Beer; Joanne M Wroblewski; Nancy R Webb; Frederick C de Beer
Journal:  Cytokine       Date:  2012-11-17       Impact factor: 3.861

2.  Thermal transitions in serum amyloid A in solution and on the lipid: implications for structure and stability of acute-phase HDL.

Authors:  Shobini Jayaraman; Christian Haupt; Olga Gursky
Journal:  J Lipid Res       Date:  2015-05-28       Impact factor: 5.922

3.  A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil.

Authors:  C J Furlaneto; A Campa
Journal:  Biochem Biophys Res Commun       Date:  2000-02-16       Impact factor: 3.575

4.  Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein, promoting SAA aggregation.

Authors:  Fredrik Noborn; John B Ancsin; Wimal Ubhayasekera; Robert Kisilevsky; Jin-Ping Li
Journal:  J Biol Chem       Date:  2012-05-31       Impact factor: 5.157

5.  Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans.

Authors:  Tsuyoshi Chiba; Mary Y Chang; Shari Wang; Thomas N Wight; Timothy S McMillen; John F Oram; Tomas Vaisar; Jay W Heinecke; Frederick C De Beer; Maria C De Beer; Alan Chait
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-07       Impact factor: 8.311

6.  Reduced leucocyte cholesteryl ester transfer protein expression in acute coronary syndromes.

Authors:  D Ye; A O Kraaijeveld; R W Grauss; S M Willems; L C van Vark-van der Zee; S C A de Jager; M Jauhiainen; J A Kuivenhoven; G M Dallinga-Thie; D E Atsma; P C W Hogendoorn; E A L Biessen; T J C Van Berkel; J W Jukema; M van Eck
Journal:  J Intern Med       Date:  2008-09-06       Impact factor: 8.989

7.  Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function.

Authors:  R L Meek; S Urieli-Shoval; E P Benditt
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

8.  LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management.

Authors:  William C Cromwell; James D Otvos; Michelle J Keyes; Michael J Pencina; Lisa Sullivan; Ramachandran S Vasan; Peter W F Wilson; Ralph B D'Agostino
Journal:  J Clin Lipidol       Date:  2007-12       Impact factor: 4.766

9.  Deficiency of endogenous acute phase serum amyloid A does not affect atherosclerotic lesions in apolipoprotein E-deficient mice.

Authors:  Maria C De Beer; Joanne M Wroblewski; Victoria P Noffsinger; Debra L Rateri; Deborah A Howatt; Anju Balakrishnan; Ailing Ji; Preetha Shridas; Joel C Thompson; Deneys R van der Westhuyzen; Lisa R Tannock; Alan Daugherty; Nancy R Webb; Frederick C De Beer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-11-21       Impact factor: 8.311

10.  Effects of KDT501 on Metabolic Parameters in Insulin-Resistant Prediabetic Humans.

Authors:  Philip A Kern; Brian S Finlin; Dorothy Ross; Tania Boyechko; Beibei Zhu; Neile Grayson; Robert Sims; Jeffrey S Bland
Journal:  J Endocr Soc       Date:  2017-04-21
View more
  25 in total

Review 1.  Role of serum amyloid A in atherosclerosis.

Authors:  Preetha Shridas; Lisa R Tannock
Journal:  Curr Opin Lipidol       Date:  2019-08       Impact factor: 4.776

2.  Structural Basis for Lipid Binding and Function by an Evolutionarily Conserved Protein, Serum Amyloid A.

Authors:  Nicholas M Frame; Meera Kumanan; Thomas E Wales; Asanga Bandara; Marcus Fändrich; John E Straub; John R Engen; Olga Gursky
Journal:  J Mol Biol       Date:  2020-02-06       Impact factor: 5.469

3.  Serum amyloid A is not incorporated into HDL during HDL biogenesis.

Authors:  Ailing Ji; Xuebing Wang; Victoria P Noffsinger; Drew Jennings; Maria C de Beer; Frederick C de Beer; Lisa R Tannock; Nancy R Webb
Journal:  J Lipid Res       Date:  2020-01-08       Impact factor: 5.922

4.  Human Serum Amyloid a Impaired Structural Stability of High-Density Lipoproteins (HDL) and Apolipoprotein (Apo) A-I and Exacerbated Glycation Susceptibility of ApoA-I and HDL.

Authors:  Kyung-Hyun Cho
Journal:  Molecules       Date:  2022-07-01       Impact factor: 4.927

Review 5.  Annual Report on Sex in Preclinical Studies: Arteriosclerosis, Thrombosis, and Vascular Biology Publications in 2018.

Authors:  Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-12-23       Impact factor: 8.311

6.  Sexually Dimorphic Relationships Among Saa3 (Serum Amyloid A3), Inflammation, and Cholesterol Metabolism Modulate Atherosclerosis in Mice.

Authors:  Alan Chait; Shari Wang; Leela Goodspeed; Diego Gomes; Katherine E Turk; Tomasz Wietecha; Jingjing Tang; Carl Storey; Kevin D O'Brien; Katya B Rubinow; Chongren Tang; Tomas Vaisar; Sina A Gharib; Aldons J Lusis; Laura J Den Hartigh
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-03-25       Impact factor: 10.514

7.  Effect of niacin monotherapy on high density lipoprotein composition and function.

Authors:  Scott M Gordon; Marcelo J Amar; Kianoush Jeiran; Michael Stagliano; Emma Staller; Martin P Playford; Nehal N Mehta; Tomas Vaisar; Alan T Remaley
Journal:  Lipids Health Dis       Date:  2020-08-21       Impact factor: 3.876

8.  Synergy between serum amyloid A and secretory phospholipase A2.

Authors:  Shobini Jayaraman; Marcus Fändrich; Olga Gursky
Journal:  Elife       Date:  2019-05-21       Impact factor: 8.140

9.  Silencing of SAA1 inhibits palmitate- or high-fat diet induced insulin resistance through suppression of the NF-κB pathway.

Authors:  Yong Wang; Feng Cao; Yang Wang; Gang Yu; Ben-Li Jia
Journal:  Mol Med       Date:  2019-05-06       Impact factor: 6.354

10.  Serum amyloid A protein has been undervalued as a biomarker of COVID-19.

Authors:  Carlos-Alberto Gonçalves; Patrícia Sesterheim
Journal:  Diabetes Metab Res Rev       Date:  2020-07-18       Impact factor: 8.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.